Meeting
2012 ASCO Annual Meeting
A phase I study of chronically dosed, single-agent veliparib (ABT-888) in patients (pts) with either BRCA 1/2-mutated cancer (BRCA+), platinum-refractory ovarian cancer, or basal-like breast cancer (BRCA-wt).
Authors
Shannon Leigh Huggins-Puhalla
University of Pittsburgh Cancer Institute, Magee-Womens Hospital, Pittsburgh, PA
Shannon Leigh Huggins-Puhalla , Jan Hendrik Beumer , Leonard Joseph Appleman , Hussein Abdul-Hassan Tawbi , Ronald G. Stoller , Yan Lin , Brian Kiesel , Antoinette R. Tan , Darlene Gibbon , Yixing Jiang , Agustin Garcia , Helen K. Chew , Robert Morgan , Stacie Peacock Shepherd , Vincent L. Giranda , Alice P. Chen , Chandra Prakash Belani , Edward Chu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics - Experimental Therapeutics
Track
Developmental Therapeutics
Sub Track
DNA Repair and Apoptosis
Clinical Trial Registration Number
NCT00892736
Citation
J Clin Oncol 30, 2012 (suppl; abstr 3054)
DOI
10.1200/jco.2012.30.15_suppl.3054
Abstract #
3054
Poster Bd #
14D
Abstract Disclosures
Similar Posters
Poster
2014 Breast Cancer Symposium
Outcome of BRCA 1/2-Mutated (BRCA+) and triple-negative, BRCA wild type (BRCA-wt) breast cancer patients in a phase I study of single-agent veliparib (V).
First Author: Shalu Pahuja
Poster
2018 ASCO Annual Meeting
Phase I clinical trials evaluating olaparib in combination with radiotherapy (RT) and/or temozolomide (TMZ) in glioblastoma patients: Results of OPARATIC and PARADIGM phase I and early results of PARADIGM-2.
First Author: Anthony J. Chalmers
Poster
2017 ASCO Annual Meeting
Phase 1/2 study of veliparib (V) combined with carboplatin (Cb) and etoposide (E) in patients (pts) with extensive-stage disease (ED) small cell lung cancer (SCLC) and other solid tumors: Phase 1 results.
First Author: Florence Atrafi
Poster
2013 ASCO Annual Meeting
Phase I adult brain tumor consortium (ABTC) trial of ABT-888 (veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK) data.
First Author: Lawrence Kleinberg